← Back to Clinical Trials
RecruitingNCT06015711
The Effect of Preoperative Maxigesic® on Intraoperative Remifentanil Requirement
◆ AI Clinical Summary
Plain-language summary for patients
Trial Parameters
ConditionOpioid Use
SponsorAjou University School of Medicine
Study TypeINTERVENTIONAL
PhaseN/A
Enrollment96
SexALL
Min Age19 Years
Max Age60 Years
Start Date2023-08-30
Completion2026-08-31
Interventions
Maxigesic administration
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Maxigesic is combined intravenous analgesic of ibuprofen and acetaminphen. The purpose of this study is investigate weather preoperative Maxigesic administration can reduce intraoperative remifentanil requirement.
Eligibility Criteria
Inclusion Criteria: * Adult patients (19-60 years old) with ASA physical status 1, 2, 3 * Scheduled surgery under general anesthesia Exclusion Criteria: * The patient does not conset * Pregnancy * hepatic disorder * Renal disorder * Asthma * Hypersensitivity to the NSAIDs or acetaminophen * Patients receiving chronic pain therapy * Drug dependence * Patients taking psychiatric drugs * Alcoholics * History of gastrointestinal ulcer or bleeding
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology